Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Istvan Majer"'
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Aims: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM). Methods: We estimated the increase in survival attributable
Externí odkaz:
https://doaj.org/article/1a62d024e7a0434d8d6aa66de04d4deb
Autor:
Ralph Schmidt, Istvan Majer, Natalia García Román, Alejandra Rivas Basterra, ElizaBeth Grubb, Constancio Medrano López
Publikováno v:
Health Economics Review, Vol 7, Iss 1, Pp 1-14 (2017)
Abstract Background Respiratory syncytial virus (RSV) infection remains one of the major reasons of re-hospitalization among children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus p
Externí odkaz:
https://doaj.org/article/969d4a49940846aca94bdf0d0412d017
Publikováno v:
BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-10 (2017)
Abstract Background Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However, little is known about
Externí odkaz:
https://doaj.org/article/9d736f28002e45b4896858729e27bf16
Autor:
Megane Caillon, Benoit Brethon, Chrissy van Beurden-Tan, Romain Supiot, Antoine Le Mezo, Jean-Vannak Chauny, Istvan Majer, Arnaud Petit
Publikováno v:
PharmacoEconomics - Open.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad7d8af692e124251a4427194fb4a7c6
https://doi.org/10.1007/s41669-023-00411-4
https://doi.org/10.1007/s41669-023-00411-4
Autor:
Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Meletios A. Dimopoulos, Sachin Patel, Istvan Majer, Andriani Fetani, Christos Boukis, Evangelos Terpos
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S172-S173
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ad6597aa81746eac79f92916bd71505
https://doi.org/10.1016/s2152-2650(22)00579-1
https://doi.org/10.1016/s2152-2650(22)00579-1
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 25(4)
Objectives State-transition models (STMs) applied in oncology have given limited considerations to modeling postprogression survival data. This study presents an application of an STM focusing on methods to evaluate the postprogression transition and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61043181dbf4bb9865e70e53a985a3d9
https://pubmed.ncbi.nlm.nih.gov/35365303
https://pubmed.ncbi.nlm.nih.gov/35365303
Publikováno v:
Therapeutic Advances in Hematology
Therapeutic Advances in Hematology, Vol 12 (2021)
Therapeutic Advances in Hematology, Vol 12 (2021)
Aims: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM). Methods: We estimated the increase in survival attributable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b3e9e3277a912cde46d7f560a06ccd
https://pubmed.ncbi.nlm.nih.gov/34276923
https://pubmed.ncbi.nlm.nih.gov/34276923
Autor:
Eva Hellqvist Franck, Vishal Patel, Lucie Kutikova, Hareth Nahi, Aaron Levine, Maria Svensson, Ying Qu, Markus Hansson, Istvan Majer, Göran Wålinder
Publikováno v:
Acta Haematol
Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b4b22ab8392aaf7588c57d8edd37bb
https://pubmed.ncbi.nlm.nih.gov/33631745
https://pubmed.ncbi.nlm.nih.gov/33631745
Autor:
Istvan Majer, Rohan Medhekar, Shaji Kumar, Meletios A. Dimopoulos, Sumeet Panjabi, Marco Campioni
In the US, carfilzomib 70 mg⁄m2 once-weekly plus dexamethasone (Kd70 QW) was recently indicated for relapsed and/or refractory multiple myeloma. In current US clinical practice, most patients treated with Kd receive carfilzomib at a previously appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91cf1a99609c797cc21145c6bb97be36
Autor:
Ivan Houisse, Sumeet Panjabi, Ágnes Benedict, Istvan Majer, Marco Campioni, Sikander Ailawadhi, Andrzej Jakubowiak
Publikováno v:
Expert Review of Hematology. 10:1107-1119
We assessed the economic value of carfilzomib 56 mg/mCost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02b7c91c361b20b5481dfa789a11123
https://doi.org/10.1080/17474086.2017.1391088
https://doi.org/10.1080/17474086.2017.1391088